Apex Biotechnology Corp.

Informe acción TWSE:1733

Capitalización de mercado: NT$2.9b

Salud financiera de hoja de balance de Apex Biotechnology

Salud financiera controles de criterios 6/6

Apex Biotechnology tiene un patrimonio de accionistas total de NT$1.8B y una deuda total de NT$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son NT$2.3B y NT$557.6M respectivamente. El BAIT de Apex Biotechnology es de NT$119.0M, por lo que su ratio de cobertura de intereses es de 253.8. Tiene efectivo e inversiones a corto plazo que ascienden a NT$466.8M.

Información clave

0%

Ratio deuda-patrimonio

NT$0

Deuda

Ratio de cobertura de intereses253.8x
EfectivoNT$466.79m
PatrimonioNT$1.78b
Total pasivoNT$557.62m
Activos totalesNT$2.34b

Actualizaciones recientes sobre salud financiera

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Mar 30
Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Dec 16
These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Recent updates

Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings

Nov 21
Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings

Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Aug 06
Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Mar 21
Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Apr 17
Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Mar 30
Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Mar 10
Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

Feb 17
Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

Jan 27
A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

Jan 06
Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Dec 16
These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Nov 22
Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (NT$1.6B) de 1733 superan a sus pasivos a corto plazo (NT$439.6M).

Pasivo a largo plazo: Los activos a corto plazo de 1733 (NT$1.6B) superan a sus pasivos a largo plazo (NT$118.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 1733 está libre de deudas.

Reducción de la deuda: 1733 no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 25.5%.

Cobertura de la deuda: 1733 no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: 1733 no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.

Hoja de balance

Descubre empresas con salud financiera

7D

1Y

7D

1Y

7D

1Y